ALLIANCEBERNSTEIN L.P. - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 115 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2021. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.

Quarter-by-quarter ownership
ALLIANCEBERNSTEIN L.P. ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$20,921
+14.7%
17,730
+37.0%
0.00%
Q2 2023$18,245
-56.6%
12,940
-52.9%
0.00%
Q1 2022$42,000
-49.4%
27,500
-18.6%
0.00%
Q4 2021$83,000
-2.4%
33,8000.0%0.00%
Q3 2021$85,000
-11.5%
33,8000.0%0.00%
Q2 2021$96,000
+15.7%
33,800
-66.3%
0.00%
Q1 2020$83,0000.0%100,200
+8.0%
0.00%
Q4 2019$83,000
-8.8%
92,8000.0%0.00%
Q3 2019$91,00092,8000.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q2 2021
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,005,379$85,694,0004.37%
Defender Capital, LLC. 4,798,270$12,707,0004.13%
Raffles Associates 93,590$236,0000.22%
Prescott General Partners LLC 1,851,851$4,667,0000.16%
DCF Advisers, LLC 87,000$219,0000.10%
Laidlaw Wealth Management LLC 104,841$264,0000.07%
Beirne Wealth Consulting Services, LLC 45,000$113,0000.06%
Strategic Wealth Investment Group, LLC 70,625$179,0000.05%
Fort Sheridan Advisors LLC 47,931$121,0000.04%
Sightline Wealth Advisors, LLC 14,958$38,0000.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders